Clinical trial in nephrology at hard end point?

被引：6

作者：

De Zeeuw, D ^{[1
]}

De Graeff, PA ^{[1
]}

机构：

[1] Univ Med Ctr Groningen, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2004年 / 15卷 / 02期

关键词：

D O I：

10.1097/01.ASN.0000113164.35698.49

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：506 / 508

页数：3

共 13 条

[1]

[Anonymous], 2003, LANCET, V361, P2167

[2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[3] The next treatments of chronic kidney disease: If we find them, can we test them? [J].

Hostetter, TH .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (12) :3024-3026

[4] THE EFFECTS OF DIETARY-PROTEIN RESTRICTION AND BLOOD-PRESSURE CONTROL ON THE PROGRESSION OF CHRONIC RENAL-DISEASE [J].

KLAHR, S ;

LEVEY, AS ;

BECK, GJ ;

CAGGIULA, AW ;

HUNSICKER, L ;

KUSEK, JW ;

STRIKER, G ;

BUCKALEW, V ;

BURKART, J ;

FURBERG, C ;

FELTS, J ;

MOORE, M ;

ROCCO, H ;

DOLECEK, T ;

WARREN, S ;

BEARDEN, B ;

STARKEY, C ;

HARVEY, J ;

POOLE, D ;

DAHLQUIST, S ;

DOROSHENKO, L ;

BRADHAM, K ;

WEST, D ;

AGOSTINO, J ;

COLE, L ;

BAKER, B ;

HAIRSTON, K ;

BURGOYNE, S ;

LAZARUS, J ;

STEINMAN, T ;

SEIFTER, J ;

DESMOND, M ;

FIORENZO, M ;

CHIAVACCI, A ;

METALIDES, T ;

KORZECRAMIREZ, D ;

GOULD, S ;

PICKETT, V ;

PORUSH, J ;

FAUBERT, P ;

SPITALEWITZ, S ;

FAUBERT, J ;

ZIMMER, G ;

SAUM, D ;

BLOCK, M ;

WOEL, J ;

ROSE, M ;

DENNIS, V ;

SCHWAB, S ;

MINDA, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (13) :877-884

[5] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[6] THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].

LEWIS, EJ ;

HUNSICKER, LG ;

BAIN, RP ;

ROHDE, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462

[7] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:: the CHARM-Added trial [J].

McMurray, JJV ;

Östergren, J ;

Swedberg, K ;

Granger, CB ;

Held, P ;

Michelson, EL ;

Olofsson, B ;

Yusuf, S ;

Pfeffer, MA .

LANCET, 2003, 362 (9386) :767-771

[8] RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (Retracted article. See vol. 374, pg. 1226, 2009) [J].

Nakao, N ;

Yoshimura, A ;

Morita, H ;

Takada, M ;

Kayano, T ;

Ideura, T .

LANCET, 2003, 361 (9352) :117-124

[9] A decline in the US share of research articles [J].

Rahman, M ;

Fukui, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (15) :1211-1212

[10] Prospective trials on anemia of chronic disease:: The Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) [J].

Rao, M ;

Pereira, BJG .

KIDNEY INTERNATIONAL, 2003, 64 :S12-S19

← 1 2 →